Fig. 2

Cumulative incidence functions of antiseizure medication gaps of increasing durations. Legend: The outcome was time to the first day of the first gap in antiseizure medication pill supply of each specified number of days. The outcome was censored if a competing risk occurred before a fill gap - death, emergency room or inpatient visit listing seizures as a diagnosis, or losing part D coverage. Overall, 5191 (24%) had a 30-day ASM gap, 1753 (8%) had a 90-day gap, 803 (4%) had a 180-day gap, and 381 (2%) had a 360-day gap. Curves do not extend until 1/1/2019 because a sufficient number of days were required to evaluate the outcome (e.g. 30, 90, 180, or 360 days before 1/1/2019). On 1/1/2018, at which point all outcomes were measurable, cumulative incidences were 20, 6, 3, and 2% for 30-, 90-, 180-, and 360-day gaps, respectively. Dashed lines represent 95% confidence intervals